How does follistatin compare to finasteride or dutasteride for treating androgenic alopecia?

Androgenic alopecia, also known as male or female pattern baldness, is the most common form of hair loss in both men and women. It is characterized by a gradual thinning of hair in specific patterns and is primarily driven by the effects of dihydrotestosterone (DHT), a hormone derived from testosterone. DHT binds to androgen receptors in hair follicles and gradually causes their miniaturization, eventually leading to the production of shorter, finer hairs and the cessation of hair growth altogether.

The two most commonly used prescription treatments today are finasteride and dutasteride, both of which work by lowering DHT levels. Another molecule, follistatin, attracts attention in hair-loss discussions. Unlike the other two, follistatin does not act on DHT or androgen metabolism, which is an entirely different approach to the condition. It is not free of hormonal effects, though: it was named for suppressing follicle-stimulating hormone, a reproductive hormone. It is also, unlike them, experimental: there is no approved follistatin medicine for hair loss. This article compares what is published about each.

Finasteride and Dutasteride: Blocking DHT at the Source

Finasteride, sold as Propecia among other names, is a type II 5-alpha-reductase inhibitor. That enzyme converts testosterone into DHT, the androgen primarily responsible for follicular miniaturization. By inhibiting this conversion, finasteride reduces DHT levels in the scalp and bloodstream, reducing the hormonal signal behind the miniaturization.

Dutasteride inhibits both type I and type II 5-alpha-reductase, so it suppresses DHT more completely. A randomized, placebo-controlled trial by Olsen and colleagues, published in the Journal of the American Academy of Dermatology in 2006, enrolled 416 men aged 21 to 45 with androgenetic alopecia and ran for 24 weeks. It compared several daily doses of dutasteride against finasteride 5 mg and placebo, and measured outcomes with standardized global photography, investigator assessment and hair counts. The authors reported that dutasteride increased hair count and width dose-dependently, and that the highest dose tested outperformed finasteride at 24 weeks. Note that the dose which outperformed finasteride in that trial was well above the 0.5 mg dutasteride dose used clinically, and that the finasteride comparator was 5 mg rather than the 1 mg licensed for hair loss.

A later head-to-head trial by Gubelin Harcha and colleagues, published in the same journal in 2014, compared dutasteride and finasteride at the doses actually used for hair loss in men with androgenetic alopecia. That trial randomised 917 men and reported dutasteride 0.5 mg daily to be superior to finasteride 1 mg daily on hair count at 24 weeks; it lasted only 24 weeks, so it does not show how the two compare over years. Separately, Eun and colleagues reported a phase III placebo-controlled trial of dutasteride 0.5 mg daily in men with male pattern hair loss in 2010.

Reported side effects

Both drugs were associated with sexual side effects in these trials, including decreased libido and erectile dysfunction. Those effects were reported by a minority of participants, but the labels for both drugs list them, and the potential for hormonal effects is the main reason these are prescription-only medicines.

Follistatin: A Regenerative Angle Rather Than a Hormonal One

Follistatin is a glycoprotein that binds to and neutralizes members of the TGF-beta superfamily, particularly activin and myostatin. In laboratory systems, this removes inhibitory signals that limit cellular proliferation and differentiation. Where finasteride and dutasteride suppress a hormone, follistatin is described as acting on the regenerative environment of the hair follicle.

That is a different kind of mechanism: rather than acting on androgens, follistatin is described as influencing stem-cell activation, cellular repair, and follicular proliferation. In principle it would not stop DHT-driven loss but might support regeneration of follicular structures. In practice, almost none of this has been tested in people.

The one human study that can be verified is a first-in-man phase 1 trial by Zimber and colleagues, published in the Journal of Drugs in Dermatology in 2011. It gave men with androgenetic alopecia a single intradermal injection of a cell-derived preparation containing Wnt proteins and follistatin, and reported increases in hair shaft thickness and terminal hair density. A phase 1 trial is a small, short, safety-focused first step. It is not evidence of efficacy comparable to the 5-alpha-reductase inhibitor trials described above, and no larger controlled trial has followed it into practice.

Comparing the Mechanisms: Suppression Versus Regeneration

Finasteride and dutasteride reduce DHT, which is how they slow further damage to hair follicles. They are not described as regenerating follicles that have already been lost or severely miniaturized. That makes them treatments aimed at halting loss and recovering miniaturized hairs, rather than restoring follicles that are gone.

Follistatin is proposed as a different approach, aimed at the regenerative environment of the follicle rather than at the hormone. Preclinical work has been read as suggesting it could push dormant follicles into the anagen phase; that has not been demonstrated in a controlled human trial. The proposed mechanism also does not address the androgenic driver of the condition, so DHT-driven miniaturization would be expected to continue unless follistatin were combined with a DHT inhibitor — a combination nobody has tested.

Safety Profiles: Documented Hormonal Risks Versus the Unknown

Finasteride and dutasteride have documented side effects tied to their hormonal mechanism. Sexual dysfunction, decreased libido, breast tenderness, and mood changes appear in their labels and in trial reports. In trials these were reported at low rates during treatment, but they can matter a great deal to the individual affected.

Since approval, some men have reported sexual problems that continued after they stopped these drugs, including low libido, erection and ejaculation problems. The US, UK and EU product information all describe these reports. The US finasteride label also lists depression and suicidal thoughts and behavior, and the US dutasteride label says sexual side effects may persist after stopping and that the drug's role in this is unknown. In 2025 the European Medicines Agency confirmed suicidal thoughts as a side effect of finasteride tablets, with a frequency that cannot be estimated. The UK medicines regulator (MHRA, May 2026) states that finasteride is associated with depression, suicidal thoughts and sexual dysfunction "which may persist after treatment is stopped." These reports come from voluntary reporting, so they cannot show how often persistent problems happen, or prove that the drug caused them in a given person.

Both drugs lower PSA, a blood test used in prostate cancer screening, so a doctor reading the result needs to know. Dutasteride stays in the body for months; its US label says men should not donate blood until at least 6 months after the last dose. Because dutasteride suppresses DHT more completely, its effect profile can differ from finasteride's.

For follistatin, there is no comparable safety information to set against that. The only human data is a single small phase 1 injection trial of a mixed product, and no human trial of topical follistatin has been published. The absence of published side effects is not evidence of safety — it usually means nobody has looked. Follistatin acts on pathways well beyond the hair follicle, including muscle growth and reproductive signalling, so systemic effects are an open question rather than a settled one. It is an experimental compound with unknown long-term safety, not a proven gentler alternative.

What We Still Don't Know

The largest gap for follistatin is the absence of large, long-term, placebo-controlled human trials. What exists is laboratory work plus one small phase 1 study. How effective follistatin would be over a full hair cycle, how well it penetrates the scalp when applied topically, and how it interacts with other hair-loss treatments are all unanswered.

Finasteride and dutasteride, by contrast, have been studied extensively and carry regulatory approvals — finasteride 1 mg is approved for male pattern hair loss in many countries; dutasteride is approved for that use in some countries and prescribed off-label for it in others. Their trials support slowing or partially reversing loss, alongside the documented risks. Establishing follistatin as a treatment for androgenic alopecia would require trials in diverse populations with standardized outcome measures and head-to-head comparison against those existing treatments.

Talk to a doctor or pharmacist before starting, stopping or combining finasteride or dutasteride, and before considering any experimental or injectable compound such as follistatin. Finasteride and dutasteride can cause birth defects in a male fetus: they must not be taken by anyone who is pregnant or may become pregnant, and women who are or may be pregnant should not handle crushed or broken finasteride tablets or leaking dutasteride capsules. The UK regulator (MHRA, May 2026) advises stopping finasteride 1 mg immediately and contacting a doctor if depression or suicidal thoughts develop.

User Experiences

Follistatin comes up among members of the Tressless community who are looking for alternatives or adjuncts to established treatments like finasteride and dutasteride. The discussions reflect both curiosity and skepticism. Some users are interested in the biological mechanism — the inhibition of activin and myostatin — while the recurring view in those threads is that the evidence is preliminary and experimental.

One user noted that follistatin has been shown to promote muscle growth in mice and has been linked to improved follicular activity when injected alongside growth factors. Other posters tempered that by pointing out the results come from animal models or very early-stage clinical research. Commenters repeatedly contrasted this with finasteride and dutasteride, whose effects on DHT have been measured in large trials, and noted that follistatin's effect on human scalp hair remains speculative.

Another user pointed to an older post referencing injections of follistatin combined with other growth factors and some reported improvement in regrowth. Responses were cautious, citing the lack of long-term follow-up and the absence of any available product. Several posters said they preferred to stay with finasteride and dutasteride because those have trial evidence and a defined prescribing framework.

In a separate discussion, community members cited the phase 1 trial combining Wnt proteins and follistatin. The treatment was described as appearing safe with modest efficacy, and users again stressed the need for larger controlled trials before treating follistatin as an option. The proposed mechanism — blocking activin rather than lowering DHT — appealed to those wary of hormonal treatments, but the absence of any commercial product or clinical guidance kept it theoretical.

Most users in these threads conclude that follistatin, however interesting biologically, does not yet offer a comparable alternative to finasteride or dutasteride. They describe those 5α-reductase inhibitors as the core drug treatment for androgenic alopecia, because their effect on scalp DHT and on miniaturization has been measured in controlled trials. Until human research establishes follistatin's safety and effectiveness, it is likely to stay at the edge of hair-loss treatment discussions.

References

Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., & Rittmaster, R. S. (2006). The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology, 55(6), 1014–1023. PMID: 17110217. https://pubmed.ncbi.nlm.nih.gov/17110217/

Gubelin Harcha, W., Barboza Martínez, J., Tsai, T. F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Journal of the American Academy of Dermatology, 70(3), 489–498.e3. PMID: 24411083. https://pubmed.ncbi.nlm.nih.gov/24411083/

Eun, H. C., Kwon, O. S., Yeon, J. H., Shin, H. S., Kim, B. Y., Ro, B. I., Cho, H. K., Sim, W. Y., Lew, B. L., Lee, W. S., Park, H. Y., Hong, S. P., & Ji, J. H. (2010). Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. Journal of the American Academy of Dermatology, 63(2), 252–258. PMID: 20605255. https://pubmed.ncbi.nlm.nih.gov/20605255/

Organon. Propecia (finasteride) tablets — prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36

Avodart (dutasteride) capsules — prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=960797b3-09b1-4d6a-8ece-8b5d918e93e4

European Medicines Agency. (2025). Finasteride- and dutasteride-containing medicinal products — Article 31 referral. https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction. Drug Safety Update. https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction

Zimber, M. P., Ziering, C., Zeigler, F., Hubka, M., & Mansbridge, J. N. (2011). Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial. Journal of Drugs in Dermatology, 10(11), 1308–1312. PMID: 22052313. https://pubmed.ncbi.nlm.nih.gov/22052313/

Reddit user. Follistatin — thoughts about a potential treatment. https://reddit.com/r/tressless/comments/16f1m6n/follistatin_thoughts_about_a_potential_treatment/

Reddit user. Injections of follistatin and growth factors. https://reddit.com/r/tressless/comments/ud92t/injections_of_follistatin_and_growth_factors/

Reddit user. Hair regrowth following a Wnt and follistatin treatment. https://reddit.com/r/tressless/comments/27aycv/hair_regrowth_following_a_wnt_and_follistatin/